125 related articles for article (PubMed ID: 38939675)
1. Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry.
Gwechenberger M; Barón-Esquivias G; de Vries TAC; Siller-Matula JM; Manu MC; Souza JAG; Wienerroither S; Pecen L; de Groot JR; De Caterina R; Kirchhof P;
JACC Adv; 2024 Apr; 3(4):100880. PubMed ID: 38939675
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
[TBL] [Abstract][Full Text] [Related]
3. Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care.
Kirchhof P; Pecen L; Bakhai A; de Asmundis C; de Groot JR; Deharo JC; Kelly P; Levy P; Lopez-de-Sa E; Monteiro P; Steffel J; Waltenberger J; Weiss TW; Laeis P; Manu MC; Souza J; De Caterina R
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):47-57. PubMed ID: 35881467
[TBL] [Abstract][Full Text] [Related]
4. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
[TBL] [Abstract][Full Text] [Related]
5. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.
de Groot JR; Weiss TW; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Waltenberger J; Steffel J; Levy P; Bakhai A; Zierhut W; Laeis P; Manu MC; Reimitz PE; De Caterina R; Kirchhof P
Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f30-f39. PubMed ID: 32790837
[TBL] [Abstract][Full Text] [Related]
6. Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data.
Monteiro P
Rev Port Cardiol (Engl Ed); 2020 Nov; 39(11):651-662. PubMed ID: 33190965
[TBL] [Abstract][Full Text] [Related]
7. Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry.
Boriani G; De Caterina R; Manu MC; Souza J; Pecen L; Kirchhof P
J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34209595
[TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program.
De Caterina R; Kim YH; Koretsune Y; Wang CC; Yamashita T; Chen C; Reimitz PE; Unverdorben M; Kirchhof P
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33546442
[TBL] [Abstract][Full Text] [Related]
9. Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study.
Kirchhof P; Bakhai A; de Asmundis C; de Groot JR; Deharo JC; Kelly P; Lopez-de-Sa E; Monteiro P; Fronk EM; Lamparter M; Laeis P; Smolnik R; Steffel J; Waltenberger J; Weiss TW; De Caterina R;
Int J Cardiol; 2024 Aug; 408():132118. PubMed ID: 38697397
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study.
de Vries TAC; Hemels MEW; Cools F; Crijns HJGM; Yperzeele L; Vanacker P; Blankoff I; Lancellotti P; Mairesse GH; de Veer A; Casado Arroyo R; Catez E; de Pauw M; Vanassche T; de Asmundis C; Kirchhof P; De Caterina R; de Groot JR;
Acta Cardiol; 2021 Jun; 76(4):431-439. PubMed ID: 33406996
[TBL] [Abstract][Full Text] [Related]
11. Edoxaban treatment in atrial fibrillation in routine clinical care: One-year outcomes of the prospective observational ETNA-AF study in South Korean patients.
Choi EK; Choi JI; Park HS; Hwang GS; Joung B; Kim JY; Kim DH; Shin DG; Park HW
J Arrhythm; 2023 Aug; 39(4):546-555. PubMed ID: 37560283
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study.
de Vries TAC; Hemels MEW; Cools F; Crijns HJGM; Yperzeele L; Vanacker P; Blankoff I; Lancellotti P; Mairesse GH; de Veer A; Casado Arroyo R; Catez E; de Pauw M; Vanassche T; de Asmundis C; Kirchhof P; De Caterina R; de Groot JR;
Neth Heart J; 2021 Mar; 29(3):158-167. PubMed ID: 33411231
[TBL] [Abstract][Full Text] [Related]
13. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
Kuroda M; Tamiya E; Nose T; Ogimoto A; Taura J; Imamura Y; Fukuzawa M; Hayashi T; Akao M; Yamashita T; Lip GYH; Okumura K
JAMA Cardiol; 2022 Jun; 7(6):583-590. PubMed ID: 35416910
[TBL] [Abstract][Full Text] [Related]
14. Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation Patients From Asia - One-Year Data From the Global ETNA-AF Program.
Choi JI; Kiatchoosakun S; Jiampo P; Tse HF; Soo YOY; Wang CC; Lee CH; Pecen L; Unverdorben M; De Caterina R; Kirchhof P
Circ Rep; 2024 Mar; 6(3):86-93. PubMed ID: 38464984
[No Abstract] [Full Text] [Related]
15. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
Fordyce CB; Hellkamp AS; Lokhnygina Y; Lindner SM; Piccini JP; Becker RC; Berkowitz SD; Breithardt G; Fox KA; Mahaffey KW; Nessel CC; Singer DE; Patel MR;
Circulation; 2016 Jul; 134(1):37-47. PubMed ID: 27358435
[TBL] [Abstract][Full Text] [Related]
16. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
[TBL] [Abstract][Full Text] [Related]
17. Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients - A Subanalysis of the ENVISAGE-TAVI AF Trial.
Watanabe Y; Hayashida K; Yamamoto M; Yamanaka F; Yamasaki K; Naganuma T; Ohno Y; Yamawaki M; Morioka N; Mizutani K; Tada N; Ueno H; Nishina H; Izumo M; Nakajima Y; Ando K; Takagi K; Kimura T; Sugio K; Dangas G; Van Mieghem NM; Hengstenberg C; Chen C; Jin J; Unverdorben M; Saito S
Circ J; 2022 Oct; 86(11):1756-1763. PubMed ID: 35965066
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry.
Schnabel RB; Ameri P; Siller-Matula JM; Diemberger I; Gwechenberger M; Pecen L; Manu MC; Souza J; De Caterina R; Kirchhof P
Europace; 2023 Aug; 25(9):. PubMed ID: 37713182
[TBL] [Abstract][Full Text] [Related]
19. Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice.
Choi EK; Lin WS; Hwang GS; Kirchhof P; De Caterina R; Chen C; Unverdorben M; Wang CC; Kim YH
J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830618
[TBL] [Abstract][Full Text] [Related]
20. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
